LAS VEGAS, NV / / February 11, 2025 / Avant Technologies, Inc. (OTCQB:AVAI) ('Avant' or the 'Company'), and its partner, Ainnova Tech, Inc., (Ai ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate KLARITY, a Phase 2 clinical trial to investigate KIO-104 in patients ...

LAS VEGAS, NV / ACCESS Newswire / February 11, 2025 / Avant Technologies, Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology ...

AI has quietly revolutionized the field of ophthalmology.While the concept of AI may evoke futuristic images of robots and automation, the reality is that many of us have been integrating AI into our ...

Goldman Sachs made a significant adjustment to its stance on Regenxbio Inc . (NASDAQ:RGNX), downgrading the stock from "Buy" to "Neutral" and reducing the price target dramatically to $14.00 from the ...

Eye care and nutrition experts have stressed the importance of a balanced diet, warning that a poor diet could lead to eye ...

Good’ cholesterol may be linked to an increased risk of glaucoma in individuals over 55, while, paradoxically, ‘bad’ cholesterol may be associated with a lower risk. These findings challenge ...

Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...

Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.